Market Overview - The Shanghai Composite Index is at 3885.56 points, slightly down by 0.10%, with a total trading volume of 896.24 billion yuan [1] - As of now, 150 A-shares have surpassed the half-year line, indicating a positive market trend [1] Stocks with Significant Deviation - Notable stocks with high deviation rates include: - Aerospace Information (600271) with a deviation rate of 8.95% and a price increase of 10.00% [1] - Great Wall Electric (600192) with a deviation rate of 8.62% and a price increase of 10.02% [1] - Tiankang Biological (002100) with a deviation rate of 6.61% and a price increase of 7.35% [1] Stocks Just Above the Half-Year Line - Stocks with smaller deviation rates that have just crossed the half-year line include: - Xusheng Group (300743) with a deviation rate of 4.74% and a price increase of 7.98% [1] - Zhenxin Technology (688600) with a deviation rate of 3.68% and a price increase of 10.09% [1] - Xingye Technology (002674) with a deviation rate of 3.61% and a price increase of 10.01% [1] Additional Stocks with Positive Movement - Other stocks showing positive movement include: - Dajia Weikang (301126) with a price increase of 6.55% and a deviation rate of 3.37% [1] - Beiken Energy (002828) with a price increase of 5.04% and a deviation rate of 3.20% [1] - Huide Technology (603192) with a price increase of 3.96% and a deviation rate of 2.94% [1]

Group 1: Flu Season Overview - The flu season in China has entered a high incidence period, with flu-like cases in southern and northern provinces reaching 10.3% and 9.1% of total emergency visits, respectively, both higher than the previous week [1] - The demand for flu prevention and control has surged, prompting pharmaceutical companies to increase inventory and supply across all segments, including vaccines, diagnostics, treatments, and drug distribution [1] Group 2: Prevention Efforts - Hualan Biological Engineering Co., Ltd. has reported a significant increase in public awareness regarding flu vaccination, leading to a rise in demand orders from disease control centers compared to the same period last year [1] - The company has efficiently utilized its cold chain logistics to meet the vaccination needs across the country [1] Group 3: Diagnostic Solutions - Shengxiang Biotechnology Co., Ltd. has developed a rapid nucleic acid testing solution for respiratory infections, covering various pathogens and is suitable for outpatient, emergency, and inpatient settings [1] - The company has seen an increase in shipments of respiratory products since October and is well-prepared to meet the testing demand during the flu season [1] Group 4: Treatment Options - The industry is witnessing a collaborative approach in flu treatment, combining Western and traditional Chinese medicine [2] - Beijing Shuanglu Pharmaceutical Co., Ltd. has reported an increase in orders for its flu medications, including Oseltamivir and immune enhancers [2] - Hunan Fangsheng Pharmaceutical Co., Ltd. has noted a significant improvement in sales of respiratory products in the fourth quarter, although overall sales for the year still require monitoring [2] Group 5: Drug Distribution - From November, the sales of flu medications, particularly Oseltamivir and Mabalaoshuai (Sufuda), have seen significant growth at the pharmacy chain, Lao Bai Xing [3] - The company has initiated supply assurance plans ahead of the respiratory disease peak season, ensuring stable market supply through predictive measures and increased inventory [3] - The overall pharmaceutical industry is responding to the flu season by ramping up production and inventory, which not only meets public medication needs but also drives company performance [3]

Core Viewpoint - The company, Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd., has announced its profit distribution plan for the first three quarters of 2025, which includes a cash dividend of RMB 0.22 per 10 shares, totaling RMB 4,518,870.40, approved by the shareholders' meeting on November 13, 2025 [1][2]. Summary by Sections Shareholders' Meeting Approval - The profit distribution plan was approved at the third extraordinary shareholders' meeting held on November 13, 2025, based on a total share capital of 205,403,200 shares [1][2]. - The distribution will not include stock dividends or capital reserve transfers, with any undistributed profits carried forward to future periods [1]. Implementation of the Distribution Plan - The cash dividend of RMB 0.22 per 10 shares (before tax) will be distributed to all shareholders, with specific tax implications for different types of shareholders [2]. - The total cash dividend amounts to RMB 4,518,870.40, and adjustments will be made if the total shares change before the distribution [1][2]. Key Dates - The record date for the distribution is set for December 12, 2025, and the ex-dividend date is December 15, 2025 [3]. Distribution Method - Cash dividends will be directly credited to shareholders' accounts through their custodial securities companies on the ex-dividend date [4]. - The company will bear all legal responsibilities if there are any issues with the distribution due to changes in shareholders' accounts during the application period [4]. Adjustments Related to the Distribution - The minimum selling price for shares held by shareholders who committed to not selling within two years post-lockup will be adjusted to RMB 12.1680 per share following the cash dividend distribution [4]. - The company will also adjust the grant and exercise prices for restricted stock options in accordance with its incentive plan after the distribution is completed [4].

证券代码：301126 证券简称：达嘉维康 公告编号：2025-078 湖南达嘉维康医药产业股份有限公司 2025 年前三季度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚 假记载、误导性陈述或重大遗漏。 湖南达嘉维康医药产业股份有限公司（以下简称"公司"或"本公司"）2025 年前三季度权益分派方案已获 2025 年 11 月 13 日召开的 2025 年第三次临时股东 会审议通过，现将权益分派事宜公告如下： 一、股东会审议通过权益分派方案情况 1、公司于 2025 年 11 月 13 日召开 2025 年第三次临时股东会审议通过了《关 于 2025 年前三季度利润分配预案的议案》，同意公司以截至 2025 年 9 月 30 日公 司总股本 205,403,200 股为基数，向全体股东每 10 股派发现金红利人民币 0.22 元（含税），共计派送现金红利人民币 4,518,870.40 元（含税），本次利润分配不 送红股，不以资本公积金转增股本，剩余未分配利润结转以后年度分配。公司利 润分配方案公布后至实施前，公司总股份如因增发新股、公司回购股份、股权激 励行权等原因发 ...

Group 1 - The core viewpoint of the articles highlights the active performance of flu-related stocks in the A-share market, driven by a rising trend in acute respiratory infectious diseases in China, particularly influenza [1][2] - The National Influenza Center reported that 17 provinces in China have reached high flu levels, with expectations of peak activity in mid-December [1] - The dominant circulating strain is the H3N2 subtype, accounting for over 95% of cases, with some H1N1 and B strains also present [1] Group 2 - Recent data indicates a significant increase in orders for antiviral medications, with orders for flu-specific drugs rising nearly ninefold compared to October, particularly for Maviroc and Oseltamivir [2] - Various pharmaceutical companies have shown notable stock price increases, with Guangdong Wannianqing rising over 11% and other companies like Yisheng Pharmaceutical and Jindike also experiencing substantial gains [3] - The overall supply of flu-related medications is reported to be sufficient, with recommendations for consumers to avoid panic buying [2]

证券代码：301126 证券简称：达嘉维康 公告编号：2025-077 湖南达嘉维康医药产业股份有限公司 2025 年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会不存在否决议案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 6、本次会议的召集、召开符合《中华人民共和国公司法》《上市公司股东 会规则》《深圳证券交易所创业板股票上市规则》等有关法律、行政法规、部门 规章、规范性文件和《公司章程》的有关规定。 1 7、会议出席情况 1、会议召开的日期、时间 （1）现场会议召开时间：2025 年 12 月 1 日（星期一）14:30 （2）网络投票时间：2025 年 12 月 1 日（星期一） 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 12 月 1 日 9:15-9:25、9:30-11:30，13:00-15:00；通过深圳交易所互联网投票系统 投票的具体时间为：2025 年 12 月 1 日 9:15-15:00 期间的任意时间。 2、会议地点 ...

湖南启元律师事务所 关于湖南达嘉维康医药产业股份有限公司 2025年第四次临时股东会的 法律意见书 二零二五年十二月一日 致：湖南达嘉维康医药产业股份有限公司 湖南启元律师事务所（以下简称"本所"）接受湖南达嘉维康医药产业股份 有限公司（以下简称"公司"）的委托，指派本所律师出席了公司 2025 年第四次 临时股东会（以下简称"本次股东会"），对本次股东会的召集和召开程序、出 席会议人员及召集人的资格、表决程序和表决结果的合法有效性进行律师见证， 并发表本法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《湖 南达嘉维康医药产业股份有限公司章程》（以下简称"《公司章程》"）的有关 规定出具本法律意见书。 为出具本法律意见书，本所律师声明如下： （一）本所律师出具本法律意见书是基于公司已承诺所有提供给本所律师的 文件的正本以及经本所律师查验与正本保持一致的副本均为真实、完整、可靠， 无隐瞒、虚假或重大遗漏之处。 （二）本所律师遵循了勤勉尽责和诚 ...

Core Viewpoint - The company has launched its oseltamivir phosphate granules for the treatment of influenza amid a widespread outbreak of H1N1, ensuring a stable supply of medications to meet seasonal demand [2]. Group 1: Product Availability - The company's subsidiary, Hunan Tianji Caotang Pharmaceutical Co., Ltd., has begun selling oseltamivir phosphate granules in major offline pharmacies across the country [2]. - The medication is suitable for patients aged 2 weeks and older for the treatment of both type A and type B influenza, and for prevention in patients aged 1 year and older [2]. Group 2: Market Response - The company has a range of over-the-counter medications available in its retail pharmacies, including fever reducers and cough suppressants, to address symptomatic treatment for influenza [2]. - In response to the seasonal increase in demand, the company has developed a production plan that allows for flexible adjustments in capacity based on market sales conditions, ensuring a safe and stable supply of medications [2].

Core Points - Dajia Weikang announced the early termination of a share reduction plan by a major shareholder, Mr. Zhong Xuesong [1] - Mr. Zhong reduced his holdings by 2,050,700 shares, representing 1.00% of the company's total share capital [1] - Following the reduction, Mr. Zhong's shareholding decreased from 19,288,356 shares to 17,237,656 shares, lowering his ownership percentage from 9.39% to 8.39% [1] Summary by Categories - **Shareholder Actions** - Mr. Zhong Xuesong, a shareholder with over 5% stake, informed the company about the early termination of his share reduction plan [1] - The reduction occurred between September 1, 2025, and November 20, 2025, through centralized bidding [1] - **Shareholding Changes** - The total shares reduced were 2,050,700, which is 1.00% of the total share capital [1] - Post-reduction, Mr. Zhong's total shares held decreased to 17,237,656, resulting in a new ownership percentage of 8.39% [1]

Core Points - Dajia Weikang (301126) announced the early termination of a share reduction plan by major shareholder and director Zhong Xuesong [1] - Zhong Xuesong reduced his holdings by 2.0507 million shares, representing 1% of the company's total share capital, from September 1 to November 20 [1] - Following the reduction, Zhong's shareholding decreased from 9.39% to 8.39%, totaling 17.2377 million shares [1] Summary by Sections - **Shareholder Activity** - Zhong Xuesong, a shareholder with over 5% stake, has communicated the early termination of his share reduction plan [1] - The reduction of 2.0507 million shares occurred through centralized bidding transactions [1] - **Shareholding Changes** - After the reduction, Zhong Xuesong's total shareholding is now 17.2377 million shares [1] - The percentage of total share capital held by Zhong decreased from 9.39% to 8.39% [1] - **Future Plans** - Zhong Xuesong will not proceed with any further reductions of shares during the remaining period of the reduction plan [1]